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Ab s t r a c t
Introduction: The use of conventional imaging techniques, namely mammography (MMG) and ultrasound (US), for
breast cancer (BC) detection in women at high risk for the disease does not bring optimal results in many cases. 
Aim: The present study evaluated the effectiveness of magnetic resonance (MR) mammography (MRM) in cases
where US and MMG failed to detect suspected breast lesions.
Material and methods: The study group consisted of 379 women who had had no breast pathologies detected by US
and MMG. This group was then divided into 4 groups according to the relative risk of breast cancer development. All the
women underwent MRM, and any breast pathology detected by MRM was then verified by open surgical biopsy (OSB).
Results: Based on the MRM findings, 37 women with breast pathologies were identified. All detected pathologies
were then classified into one of the BIRADS (Breast Imaging Reporting and Data System) categories. Of these, 
33 patients underwent open surgical biopsy. There were a total of 17 benign and 16 malignant breast pathologies that
were not visualized by US and MMG. The types of malignancies found, in order of their frequency, were as follows:
invasive ductal carcinoma (11 cases), ductal carcinoma in situ (2 cases), invasive lobular carcinoma (2 cases), and lob-
ular carcinoma in situ (1 case). An analysis of MRM effectiveness in detecting BC showed 93.7% sensitivity and 64.71%
specificity.
Conclusions: All women with a 20% or greater lifetime risk of developing BC should undergo annual MRM as a diag-
nostic adjunct to US and MMG. 
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Introduction
A family history of breast cancer has long been
associated with environmental factors, but is now
attributed chiefly to genetic factors. Both a high inci-
dence of hereditary breast cancer and a family histo-
ry of pathogenic mutations that predispose a woman
to developing the disease significantly increase the
risk for breast cancer even at a young age. Strategies
for reducing the risk of breast cancer include bilater-
al mastectomy, bilateral ovariectomy, and chemopre-
vention such as the use of tamoxifen.
These radical procedures are increasingly being
replaced by the use of diagnostic imaging techniques
in order to increase the chances of early detection of
breast cancer and to maximize curative treatment.
The conventional imaging techniques used so far
in women at increased risk for breast cancer, such as
mammography (MMG) and ultrasound (US), have not
yielded optimal results, and thus the disease is still
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generally detected at a stage that does not allow for
effective treatment. At the same time, substantial
progress in improving magnetic resonance mammog-
raphy (MRM) technique has been made over the last
decade; nevertheless, the high cost of this examina-
tion, together with its limited accessibility, make its
routine use untenable. Despite this, MRM is being
increasingly used as a diagnostic adjunct to MMG and
US in cases where there is diagnostic uncertainty.
Aim
This study evaluates the effectiveness of MRM as
a diagnostic tool complementary to MMG and US for
women at increased risk for developing breast cancer.
Material and methods
Genetic testing was performed on 402 women,
aged 17-78 (mean age: 48.9 years), in collaboration
with the International Hereditary Cancer Center
(IHCC) of the Pomerania Medical University [Collabo-
ration group consisted of Prof. J. Lubiński, Dr T. Byr ski,
and L. Romańska].
The tests were performed in all women who had
developed breast or ovarian cancer or had a family
history that included at least one relative with docu-
mented breast cancer before the age of 50 years or
one relative regardless of age with ovarian cancer.
The tests were done in two phases. The patients first
received complete information regarding the aims,
rules, and the expected results of the study and were
asked to express their informed consent. They then
completed questionnaires enquiring about all known
cases of cancer in relatives of first or greater than
first degree of relationship, including the year of dis-
ease onset, and if applicable, the year of death from
the disease. Additionally, in each case a family tree
was constructed that took into consideration first-
and second-degree relatives and the complete fami-
ly history with regard to cancer. At the end of this
first phase, 5-6 ml venous blood samples were drawn
from the patients for genetic testing.
In the second phase, DNA testing was done in the
Laboratory of the IHCC, and all results, including data
from the questionnaires and family interviews, were
carefully analyzed.
Approximately 1 month prior to obtaining the
DNA results, the women were subjected to:
1. Clinical breast examination.
2. Breast US using a Hitachi 740 unit with 7.5 MHz
linear probe or Voluson 730 Pro unit with 6-12 MHz
linear probe.
3. And for those over 35 years of age, MMG (provided
it had not already been performed within the last
12 months).
All breast lesions were classified according to
MMG BIRADS categories [1].
Of the 402 women subjected to the examina-
tions, a group of 379 (94.28%), aged 17-77 years
(mean age: 47.54 years), who either had had no focal
lesions detected (BIRADS 1) or had only benign le -
sions (BIRADS 2), was identified. 
All the women underwent MRM. Furthermore,
they were divided into 4 subgroups based on the
genetic testing results as follows:
• Group I – 84 women (22.16%), aged 26-66 years
(mean: 49.12 years), who carried pathogenic muta-
tions: BRCA1 – 79 (94.05%), BRCA2 – 3 (3.57%),
CHECK2 – 2 (2.38%). Because of genetic mutations,
the risk of developing breast cancer in this group
was more than 20% [2].
• Group II – 39 women (10.29%), aged 17-72 years
(mean: 41.18 years), with confirmed hereditary
breast cancer – site specific (HBC-ss) or hereditary
breast-ovarian cancer (HBOC) syndromes. Regard-
less of the number of breast cancer cases in the
family, the risk of developing breast cancer for these
women was greater than 20% [2].
• Group III – 32 women (8.44%), aged 39-77 years
(mean: 52.32 years), who had had mastectomy or
breast-conserving therapy for breast cancer. In
these women no genetic mutations were found that
would predispose them to developing breast cancer.
Regardless of the type of operation performed, the
estimated mean risk for these patients of develop-
ing breast cancer in the bilateral breast, based on
the Claus risk tables, is greater than 4% [3]. After
breast-conserving therapy, the risk of local recur-
rence within 10 years of the surgery is approximate-
ly 7% [3, 4].
• Group IV – 224 women (59.10%), aged 19-52 years
(mean: 47.54 years), who reported single breast or
ovarian cancer cases in a family member of first or
greater than first degree of relationship. However,
the number of cancers and the age of the patient at
the time of the cancer onset did not allow for a diag-
nosis of HBC-ss or HBOC syndromes.
According to the Claus model, the estimated life-
time risk for breast cancer for these women based
on the number of cases, age, and the degree of rela-
tionship is less than 20% [3, 4].
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Magnetic resonance mammography was performed
on the menstruating women between the 6th and 
17th days of the menstrual cycle, and for all patients 
any gonadotropic hormonal administration (contracep-
tives, hormone replacement therapy, etc.) was with-
drawn at least 1 month prior to the scheduled MRM.
Magnetic resonance mammography was perform-
ed using the GEMS Signa Excite 1.5T system with
INVIVO 4-channel double breast coil with the patient
in the prone position. In unenhanced MR we used
frFSE (fast relaxation fast spin echo) T2, FSE T1 and
frFSE T2 sequences with fat saturation in the axial
view, and frFSE T2 in the sagittal view. Additionally, in
the coronal view, the SE (spin echo) T1 sequence was
used to evaluate axillary lymph nodes before con-
trast administration. Contrast-enhanced MR was per-
formed in the 3D GRE (gradient recalled echo) T1 DYN
sequence with 6-fold repetition after contrast admin-
istration, with the field of view covering the entire
breast and the acquisition time not exceeding 1 min.
The SE T1 sequence was repeated in the coronal view
in order to assess axillary lymph nodes after contrast
administration. We used a 512 × 512 matrix with
a rectangular field of view 24 cm × 38 cm, providing
4 mm thickness slices, and phase encoding along the
body axis. In all patients, Multihance contrast agent
was administered intravenously in a dose of 0.1 mmol/
l/kg body mass.
Breast lesions visualized by MRM were classified
into one of the MR BIRADS categories developed by
the American College of Radiology [5].
Those patients whose breast lesions were not
visualized by US and MMG, but were detected by
MRM, were qualified for a second-look US and their
mammograms were analyzed again. All patients with
lesions identified in such a way were referred for
open surgical biopsy after introducing the localiza-
tion needle under US or MMG guidance.
All lesions that continued to be visible only by
MRM, regardless of their BIRADS type, were subject-
ed to MR-guided needle localization open breast
biopsy (Figure 1).
Lesions detected by MRM
Second-look US + recurrent MMG analysis
Lesions not visualized
Visible only in MRM
No technical possibilities 
of such procedure
Follow-up in diagnostic imaging 
– control MMR in 6 months
Open surgical breast biopsy
Insertion of localization needle
under MRM guidens
Insertion of localization nee-
dle under US/MMG guidens
Lesions visualized
Figure 1. Diagnostic procedures used in patients with lesions detected by MRM
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Statistical analysis 
For the purpose of statistical analysis we selected
a group of women in whom breast MR revealed le -
sions that were not visualized in the previous exami-
nations. Chi square test and Fisher’s exact test were
used for the analysis of statistical significance bet -
ween histopathological findings (obtained from the
open surgical biopsies) and BIRADS categories based
on the diagnostic breast MR diagnosis. Breast cancer
true positive and true negative rates were calculated
for the individual BIRADS categories to estimate sen-
sitivity and specificity of breast MR in detecting can-
cer. The false negative rate was calculated for the
BIRADS categories 2 and 3, and the false positive rate
for the BIRADS categories 4 and 5. We also estimat-
ed the positive predictive value (PPV) for breast 
cancer in lesions categorized as BIRADS 4 and 5, and
the negative predictive value (NPV) in lesions classi-
fied as BIRADS category 2 and 3. The number of
breast cancer cases was estimated for the individual
4 groups of patients enrolled in the study. All calcula-
tions were done using SPSS 14 statistical software. 
Results
Of the 380 examined patients, 37 women (9.74%)
were identified with breast pathologies detected by
MRM that were not visualized by previous US and
MMG.
In 1 of these patients two breast pathologies
were found over a 3-year period, and we thus consid-
ered this particular case twice in the analysis. In the
remaining 343 women (90.26%), MRM did not reveal
any lesions that had not also been visualized by US
and MMG. The 37 women were then classified into
the appropriate MR BIRADS categories based on
their MRM findings (Table I).
Eight women (2.11%) had lesions interpreted as
being benign and hence were classified in group II
BIRADS. In the next 8 patients (2.11%), MRM findings
were indeterminate, and they were therefore clas-
sified in group III BIRADS. Thirteen (3.42%) and 
8 (2.11%) patients were classified in groups IV and V
BIRADS respectively, indicating a high or very high
risk of breast cancer.
All 37 women with breast lesions detected by
MRM were subjected to a second-look US, and their
mammograms were analyzed again. In 4 (10.81%) of
the women, the findings corresponded to the MRM
diagnosis and these women were subjected to either
US-guided needle localization open surgical breast
biopsy (OSBB) (3 patients) or mammography-guided
needle localization OSB (1 patient).
In the remaining 33 women (89.19%), second-
look examinations did not reveal lesions that were
visualized by MRM, and these patients were quali-
fied for OSB following MRM-guided localization of
the lesion.
In 4 (12.12%) of these women, however, a biopsy
could not be performed. In two women there were
technical problems with reaching the lesion by the
localization needle tip, and in another two, the
lesions were not visualized in the preceding OSB sec-
ond MRM, which precluded the use of the localiza-
tion needle. These patients qualified for routine fol-
low-up visualizing examinations. 
Finally, OSB was performed on 33 women, includ-
ing 29 who had had breast lesions visualized by
MRM alone, and 4 who had had pathologies visual-
ized by either MMG or US examination performed
after MRM.
The open breast biopsy histopathological findings
were correlated with MR BIRADS categories as fol-
lows:
• in BIRADS 2 group – 7 (100%) benign breast lesions,
• in BIRADS 3 group – 1 (16.67%) invasive ductal can-
cer and 5 benign lesions (83.33%),
• in BIRADS 4 group – 7 (53.84%) malignant lesions:
2 ductal carcinomas in situ (15.38%), 4 (30.77%) in -
vasive ductal carcinomas, 1 invasive lobular carci-
noma (7.69%), and 5 (46.16%) benign lesions,
• BIRADS 5 group – 8 cancers (100%): 6 invasive duc-
tal carcinomas, 1 lobular carcinoma in situ and 1 in -
vasive lobular carcinoma (Table II).
Altogether, 17 benign and 16 cancerous lesions
were visualized solely by MRM. The types of cancer-
ous lesions in the order of their frequency were as
BIRADS No. of patients Percentage
2 8 2.11
3 8 2.11
4 13 3.42
5 8 2.11
Total 37 9.75
Table I. Number of patients with lesions detect-
ed by MRM not visualized by earlier US/MMG,
classified into MR BIRADS categories
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follows: invasive ductal carcinoma (11 cases), ductal
carcinoma in situ (2 cases), invasive lobular carcino-
ma (also 2), and lobular carcinoma in situ (1 case).
Based on the above findings (especially the
BIRADS results), the sensitivity of breast MRM in
detecting malignant lesions was 93.75% and speci-
ficity 64.71%. 
The positive predictive value of MRM in detecting
cancer lesions was 71.43% and the negative predic-
tive value was 91.67%. Thus, the probability of devel-
oping breast cancer in women classified as BIRADS 4
or 5 was more than 70%, while the probability of
breast lesions being benign in women classified as
BIRADS 2 and 3 was more than 90%. Lastly, there
was one false negative result in the BIRADS 3 cate-
gory, and 6 false positive results in BIRADS 4.
We analyzed the incidence of cancer in 4 groups
of women divided according to their relative risk for
developing breast cancer. There were 12 (75%) breast
cancer cases in women with documented HBC-ss
and HBOC in group II, 3 (18.75%) cases in genetic
mutation carriers in group I, and 1 (6.25%) in a woman
with a family history of breast cancer from group IV.
There were no cases of breast cancer in group III in
those patients who had had operations for breast
cancers (Table III).
All 343 women with benign lesions detected by
US or MMG and confirmed by MRM were offered
annual clinical breast examinations, US, MMG, and
MRM. The only exceptions were those women under
30 years of age on whom MMG had not been per-
formed. The follow-up time is currently 3.5 years.
In total, 229 women (67%) were followed up ac -
cording to the protocol. In none of these did MRM
detect any breast lesions other than those diagnosed
by US and MMG.
MR BIRADS groups Total
2 3 4 5
n % n % n % n % n %
Hist-path after OSB 1 1.00 16.67 0.00 0.00 1.00 7.70 0.00 0.00 2.00 6.06
2 0.00 0.00 0.00 0.00 2.00 15.38 0.00 0.00 2.00 6.06
3 0.00 0.00 1.00 16.67 4.00 30.76 6.00 75.00 11.00 33.33
4 0.00 0.00 0.00 0.00 0.00 0.00 1.00 12.50 1.00 3.03
5 0.00 0.00 0.00 0.00 1.00 7.70 1.00 12.50 2.00 6.06
6 0.00 0.00 0.00 0.00 1.00 7.70 0.00 0.00 1.00 3.03
7 5.00 83.33 3.00 50.00 2.00 15.38 0.00 0.00 10.00 30.30
8 0.00 0.00 2.00 33.33 2.00 15.38 0.00 0.00 4.00 12.12
Total 6.00 100.00 6.00 100.00 13.00 100.00 8.00 100.00 33.00 100.00
Table II. Histopathological findings after OSB compared to MR BIRADS groups
n – number of patients, Histopathological findings after OSB:  1 – fibro-cystic lesions, 2 – ductal carcinoma in situ, 3 – invasive ductal carcinoma, 4 – lobular
carcinoma in situ, 5 – invasive lobular carcinoma, 6 – lymphatic nodule, 7 – other benign lesions (apocrine metaplasia, non-atypical hyperplasias), 8 – intra-
ductal papilloma
(χ2 (21) = 31.54, p < 0.35, Fisher test = 27.67, p < 0.12) 
Groups No. of breast cancers Percentage
I 3 18.75
II 12 75.0
III 0 0
IV 1 6.25
Total 167 100
Table III. Number of detected breast cancers in
the individual risk groups
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Discussion
A standard diagnostic protocol used for women
at increased risk for developing breast cancer in
Poland covers breast US in patients over 25 years of
age and MMG alternately with US biannually when
patients reach the age of 35. In patients with the
highest risk for breast cancer, however, this strategy
is not enough to significantly reduce the cancer risk.
Preventive administration of tamoxifen and even
bilateral mastectomy with simultaneous breast pros-
thesis implantation are also recommended [6], but
these approaches are not satisfactory for some of the
women from the high risk group; for them still other
measures with an increased capability of detecting
breast cancer need to be searched for.
Magnetic resonance mammography is not rou-
tinely performed due to the limited access and high
costs of the examination. Nevertheless, its greater
effectiveness in detecting breast cancer when com-
pared with conventional visualizing methods is in -
creasingly underlined. Magnetic resonance mam-
mography is highly sensitive in detecting occult
carcinoma which produces distant metastases [7].
In studies conducted since 2000, breast cancer
detectability in asymptomatic women at increased
risk for breast cancer has ranged from 4.6% to 7.6%
[8-10]. These findings correspond to our observa-
tions, where 16 cases of breast cancer were detected;
this number represents 4.2% of the total number of
patients involved.
The results of our study have shown that all
lesions classified as BIRADS 2 were benign. A single
case of a false negative diagnosis occurred in BIRADS
3 category, which is on the borderline, and regard-
less, the patient was qualified to have a control MRM
in 6 months. The final diagnosis in this case was low-
differentiated ductal carcinoma in situ. Moreover,
according to the current literature, a false negative
interpretation of the MRM results is quite common
in this type of cancer [7, 11]. In the BIRADS 4 catego-
ry there were 6 false positive results, which correlat-
ed with the lower specificity of the MRM reported by
other authors [8, 9]. All the lesions were accurately
classified as BIRADS 5 and did turn out to be breast
cancer.
The positive predictive value of MRM, which is
71.43% in the range of 17-88%, was estimated in
studies on the effectiveness of screening MRM in
women with a high risk of developing breast cancer
[8-10, 12].
Magnetic resonance-guided needle localization
open breast biopsy was performed on 29 women
involved in this study. There were 4 other women
with breast abnormalities detected by the second-
look US and repeated analysis of mammograms; on
these women OSB was performed after inserting the
localization needle guided by one of the imaging
methods. Such an approach allows the patient to
avoid a second MRM (for lesion localization) and so
simplifies the diagnostic procedure. We should
remember that these lesions could not be detected
without MRM diagnosis. A similar approach was
introduced in 2000; however, instead of OSB, a fine-
needle aspiration biopsy was used [13]. In successive
years this technique was abandoned for patients at
increased risk for developing breast cancer because
of the high number of false negative results [14].
In 4 patients open breast biopsy was unsuccess-
ful because of technical problems. In 2 patients the
lesions were localized deep in the upper inside quad-
rant of the breast and were therefore inaccessible for
the guiding coaxial needle. Large breast size coupled
with only lateral access for needle insertion made
this type of lesion inaccessible even for a 15 cm-long
guiding needle. The use of a bilateral coil is thus rec-
ommended for MR-guided interventions; this allows
direct access to the outside as well as inside quad-
rants of the breast [14]. 
In the other 2 patients, OSB could not be per-
formed because a second MRM (performed for lesion
localization) did not visualize the lesion. As has been
reported in different studies [10, 14], this problem
occurs in 5-8% of all MRM examinations and may be
influenced by the activity of gonadotropic hormones.
Thus withdrawing hormone therapy at least 1 month
prior to the examination and performing MRM
between the 5th and 17th days of the menstruation
cycle are legitimate recommendations. Another rea-
son OSB cannot be successfully performed may have
to do with breast compression that is too dense for
the insertion of the localization needle during the
MRM. Consequently, some investigators recommend
a control MRM without breast compression 24 h pri-
or to the examination. Additionally, according to
recently published observations, the lesions may not
appear during second MRM because of being tran-
sient breast inflammation foci [14]. 
The majority of the cancer cases were detected in
groups I and II, where the risk of developing breast
cancer was more than 20%. As many as 75% of the
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breast cancers were found in women with docu-
mented HBC-ss or HBOC (group II). Surprisingly,
these women were not carriers of BRCA1 mutations;
however, they were from families in which individu-
als from multiple generations had had cancer, often
of early onset. In our study we followed the guide-
lines of the American Cancer Society from 2007
which recommended the use of MRM in women with
a lifetime risk of breast cancer greater than 20% [2].
At the same time, MRM was not recommended for
women with a less than 20% risk of the disease, such
as our patients from groups III and IV, in only one of
whom breast cancer was actually found.
Thus there are no clear indications for performing
MRM on a regular basis in women with a hereditary
risk of breast cancer without a documented diagno-
sis of mutation or HBC-ss or HBOC syndromes. The
situation is similar for women after mastectomy; 
in such cases the risk of bilateral breast cancer is 
0.5-1.0% annually, or 5-10% more than 10 years after
the initial diagnosis [2]. For women in each of the
above situations, the risk of developing breast cancer
is less than 20%.
In studies on the effectiveness of MRM in women
at high risk for developing breast cancer, the sensi-
tivity of the examination has been shown to be in
the range of 77-100%, and the specificity in the range
of 81-90% [2, 12, 15]. In our particular study, MRM
sensitivity was about 94% and specificity 65%, i.e.,
lower than in the reported observations. 
This may reflect the interpretation of BIRADS 4
abnormalities as cancer for the purpose of statistical
analysis, even though such abnormalities would only
be considered suspicious lesions according to the
BIRADS definition. All lesions with definite features
of BC are classified as BIRADS 5.
The reduced specificity of MRM relative to its sen-
sitivity may yield more false positive results than
other visualizing methods. This may lead to having to
qualify more patients for extended diagnostic proce-
dures, second-look MRM, and open breast biopsies.
It seems that MR-guided biopsy may be a solution to
this problem and may effectively increase the speci-
ficity of MRM. The preliminary results of MRM-guid-
ed needle biopsies are comparable to those obtained
from OSB. The main advantage of the former method
is that it is less invasive, but its limited availability as
a highly specialized procedure constitutes a major
drawback.
Conclusions
All women who are carriers of BRCA1 and BRCA2
mutations and have documented HBC-ss and HBOC
syndromes should undergo MRM annually as an
adjunct to US and MMG. Second-look US and analy-
sis of mammograms should be done in all cases of
suspected focal lesions detected by MRM and not
visualized by conventional methods. This allows for
the insertion of the localization needle under the
control of US or MMG and thus avoids the relatively
difficult and time-consuming MRM-guided localiza-
tions. All external factors that have an effect on MRM
findings should be eliminated, such as hormone
replacement therapy, inappropriate day of the men-
struation cycle for performing the examination, and
excessive breast compression. Studies should con-
tinue to be done to improve MRM specificity.
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